Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
AssigneesJanssen Biotech, Inc., Tufts Medical Center, Inc.
InventorsChakra Chaulagain, Raymond Comenzo, Parul Doshi, Xun Ma, Amy Sasser
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.
Claims33
A method of treating a patient having relapsed or refractory light chain amyloidosis (AL), comprising administering to the patient in need thereof an anti-CD38 antibody which is an IgG1 isotype comprising a heavy chain variable region (VH) sequence of SEQ ID NO:
- 4 and a light chain variable region (VL) sequence of SEQ ID NO:
- 5 for a time sufficient to treat relapsed or refractory AL.
A method of induction of selective killing of CD38+ hematological cancer cells and preservation of CD38+CD34+ hematopoietic stem cells in a patient with relapsed or refractory light chain amyloidosis (AL), comprising:
- contacting CD38+ cells of the patient with an anti-CD38 antibody which is an IgG1 isotype comprising a heavy chain variable region (VH) sequence of SEQ ID NO:
- 4 and a light chain variable region (VL) sequence of SEQ ID NO:
- 5;
- wherein CD38+ hematological cancer cells within the patient are killed and CD38+CD34+ hematopoietic stem cells within the patient are preserved.
A method of performing a hematopoietic stem cell transplant (HSCT) in a patient with relapsed or refractory light chain amyloidosis (AL), comprising:
- introducing hematopoietic stem cells into the patient;
- and
- administering to the patient an anti-CD38 antibody after introduction of the hematopoietic stem cells, the anti-CD38 antibody comprising a heavy chain variable region (VH) sequence of SEQ ID NO:
- 4 and a light chain variable region (VL) sequence of SEQ ID NO:
- 5, wherein the anti-CD38 antibody is an IgG1 isotype and induces killing of CD38+ hematological cancer cells, and wherein CD38+CD34+ hematopoietic stem cells within the transplant survive.
A method of performing a hematopoietic stem cell transplant (HSCT) in a patient with relapsed or refractory light chain amyloidosis (AL), comprising:
- administering to the patient an anti-CD38 antibody which is an IgG1 isotype comprising a heavy chain variable region (VH) sequence of SEQ ID NO:
- 4 and a light chain variable region (VL) sequence of SEQ ID NO:
- 5;
- and
- introducing hematopoietic stem cells into the patient after administration of the anti-CD38 antibody, wherein the anti-CD38 antibody induces killing of CD38+ hematological cancer cells, and wherein CD38+CD34+ hematopoietic stem cells within the transplant survive.
Dependencies are inferred from the claim text.